WT1, Bcl-2, Ki-67 and Her2/Neu as diagnostic and prognostic immuno markers in ovarian serous and endometrioid carcinoma

Abstract

Background: Ovarian cancer is the fifth common cause of death due to cancer in women. It constitutes 3% of all cancers in females and 15-20% of genital malignancies. Most of the ovarian cancers are serous type followed by endometrioid type. Sometimes glands of these two carcinomas are indistinguishable histologically. It also becomes difficult to differentiate these two types when they are poorly differentiated. Aims: The aim of this study was to find out differences in immuno-markers expressions between serous and endometrioid carcinomas and association of their staining patterns with other clinicopathological prognostic factors. Materials and Methods: Immunohistochemical staining for WT1, Bcl2, Ki67 (MIB1) and Her2/Neu were done in paraffin embedded tissues of histologically diagnosed total 38 cases (21 serous and 17 endometrioid) of ovarian carcinomas and staining patterns were correlated with other clinicopathological prognostic factors. Results: Out of these 38 cases, 24 cases were in stage I/II (early stage) and 14 cases stage III/IV (advance stage). On the other hand, 16 cases were low grade, 12 cases intermediate grade and 10 cases high grade. Twenty out of 21 serous carcinomas were positive for WT1, whereas most of the endometrioid carcinomas were negative. Ki67 labeling index and Her2/Neu were higher in both higher grade and stages. On the contrary, intensity of Bcl2 staining was lower in higher grades and stages lesions. Conclusions: Use of WT1 may be useful in resolving diagnostic dilemma between serous and endometrioid carcinoma, especially in difficult cases. Ki67, Bcl2 and Her2/Neu may be used as prognostic markers.

Application of Bioinformatics Analysis to Identify Important Pathways and Hub Genes in Ovarian Cancer Affected by WT1

“…Previous studies have shown that WT1 can be used as an important marker for the diagnosis and prognosis of ovarian cancer (Basak et al;Taube et al, 2016;Gaaib, 2018;Sallum et al, 2018;Mondal et al, 2021). Our research has identified related genes and signaling pathways in ovarian cancer that are affected by WT1, and identified genes that are associated with WT1 and affect the prognosis of ovarian cancer.…”